{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:57:27Z","timestamp":1783432647769,"version":"3.54.6"},"reference-count":179,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.3960\/jslrt.19007","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T22:05:52Z","timestamp":1561673152000},"page":"72-92","source":"Crossref","is-referenced-by-count":87,"title":["Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders"],"prefix":"10.3960","volume":"59","author":[{"given":"Michihide","family":"Tokuhira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Tamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders. revised 4th ed, IARC publications. 2017; pp. 443-464."},{"key":"2","unstructured":"2 Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders. 4th ed, IARC publications. 2008. pp. 335-351."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective. Mod Rheumatol. 2018; 28: 1-8.","DOI":"10.1080\/14397595.2017.1352477"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Balandraud N, Guis S, Baptiste Meynard J <i>et al.<\/i> Long-term treatment with methotrexate or tumor necrosis factor \u03b1 inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57: 762-767.","DOI":"10.1002\/art.22783"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Yoshida Y, Takahashi Y, Yamashita H <i>et al.<\/i> Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014; 24: 763-765.","DOI":"10.3109\/14397595.2013.878016"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hashimoto A, Chiba N, Tsuno H <i>et al.<\/i> Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015; 42: 564-571.","DOI":"10.3899\/jrheum.140533"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015; 17: 212.","DOI":"10.1186\/s13075-015-0728-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Harigai M, Nanki T, Koike R <i>et al.<\/i> Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016; 26: 642-650.","DOI":"10.3109\/14397595.2016.1141740"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Hellgren K, Baecklund E, Backlin C <i>et al.<\/i> Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 2017; 69: 700-708.","DOI":"10.1002\/art.40017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Shimizu Y, Nakajima A, Inoue E <i>et al.<\/i> Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Clin Rheumatol. 2017; 36: 1237-1245.","DOI":"10.1007\/s10067-017-3634-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Chisaki Y, Aoji S, Yano Y. Analysis of adverse drug reaction risk in elderly patients using the Japanese adverse drug event report (JADER) Database. Biol Pharm Bull. 2017; 40: 824-829.","DOI":"10.1248\/bpb.b16-00930"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Mercer LK, Regierer AC, Mariette X <i>et al.<\/i> Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017; 76: 2025-2030.","DOI":"10.1136\/annrheumdis-2017-211623"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Baecklund E, Iliadou A, Askling J <i>et al.<\/i> Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 692-701.","DOI":"10.1002\/art.21675"},{"key":"14","unstructured":"14 Jaffe ES, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders. 3rd ed, IARC publications. 2001; pp. 256-271."},{"key":"15","unstructured":"15 Kurita D, Ichikawa A, Sasaki Y, et al. Clinicopathological Study of Methotrexate-Associated Lymphoproliferative Disorders in Rheumatoid Arthritis Patients: Histological Classification and Predictive Factors for Disease Progression. ASH meeting. Atlanta, #4168, 2017."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tokuhira M, Saito S, Okuyama A <i>et al.<\/i> Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018; 59: 1143-1152.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018; 182: 330-343.","DOI":"10.1111\/bjh.15263"},{"key":"18","unstructured":"18 Pfizer-Japan-Inc: Rheumatrex Proper Use Information. In: vol 21, Tokyo. 2014."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Tokuhira M, Watanabe R, Nemoto T <i>et al.<\/i> Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012; 53: 616-623.","DOI":"10.3109\/10428194.2011.625101"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Ando M, Sato Y, Takata K <i>et al.<\/i> A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders\/lymphomas. PLoS One. 2013; 8: e56741.","DOI":"10.1371\/journal.pone.0056741"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Carreras J, Yukie Kikuti Y, Miyaoka M <i>et al.<\/i> Genomic profile and pathologic features of diffuse large B-cell lymphoma subtype of methotrexate-associated lymphoproliferative disorder in rheumatoid arthritis patients. Am J Surg Pathol. 2018; 42: 936-950.","DOI":"10.1097\/PAS.0000000000001071"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol. 2014; 38: 999-1006.","DOI":"10.1097\/PAS.0000000000000225"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Yamada K, Oshiro Y, Okamura S <i>et al.<\/i> Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders. Histopathology. 2015; 67: 70-80.","DOI":"10.1111\/his.12627"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ejima-Yamada K, Oshiro Y, Okamura S <i>et al.<\/i> Epstein\u2013Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders. Virchows Arch. 2017; 470: 205-215.","DOI":"10.1007\/s00428-016-2030-x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Gion Y, Iwaki N, Takata K <i>et al.<\/i> Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017; 108: 1271-1280.","DOI":"10.1111\/cas.13249"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Inui Y, Matsuoka H, Yakushijin K <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015; 56: 3045-3051.","DOI":"10.3109\/10428194.2015.1022769"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Saito S, Suzuki K, Yoshimoto K <i>et al.<\/i> Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018; 9: 621.","DOI":"10.3389\/fimmu.2018.00621"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Takanashi S, Aisa Y, Ito C <i>et al.<\/i> Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017; 37: 1629-1633.","DOI":"10.1007\/s00296-017-3764-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology. 2017; 56: 940-946.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Tokuhira M, Tanaka Y, Takahashi Y, et al. The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse\/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders ASH meeting. San Diego, #1589, 2018.","DOI":"10.1182\/blood-2018-99-114382"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Hasenclever D, Diehl V, Armitage JO <i>et al.<\/i> A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med. 1998; 339: 1506-1514.","DOI":"10.1056\/NEJM199811193392104"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Ho CL, Lu CS, Chen JH <i>et al.<\/i> Neutrophil\/lymphocyte ratio, lymphocyte\/monocyte ratio, and absolute lymphocyte count\/absolute monocyte count prognostic score in diffuse large B-cell lymphoma: useful prognostic tools in the rituximab era. Medicine (Baltimore). 2015; 94: e993.","DOI":"10.1097\/MD.0000000000000993"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK <i>et al.<\/i> Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Oncologist. 2016; 21: 343-353.","DOI":"10.1634\/theoncologist.2015-0251"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Keane C, Tobin J, Talaulikar D <i>et al.<\/i> A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget. 2018; 9: 23620-23627.","DOI":"10.18632\/oncotarget.25306"},{"key":"35","unstructured":"35 Li N, Zhang L, Song HL <i>et al.<\/i> Prognostic impact of absolute lymphocyte count\/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer\/T-cell lymphoma. Tumour Biol. 2017; 39: 1010428317705503."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Kojima M, Itoh H, Hirabayashi K <i>et al.<\/i> Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006; 202: 679-685.","DOI":"10.1016\/j.prp.2006.05.007"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Miyazaki T, Fujimaki K, Shirasugi Y <i>et al.<\/i> Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007; 82: 1106-1109.","DOI":"10.1002\/ajh.21003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Jois RN, Gaffney K, Cane P, Nicholson AG, Wotherspoon AC. Methotrexate-associated lymphoproliferative disorder masquerading as interstitial lung disease. Histopathology. 2007; 51: 709-712.","DOI":"10.1111\/j.1365-2559.2007.02830.x"},{"key":"39","unstructured":"39 Ogasawara T, Kimura A, Yasuyama M <i>et al.<\/i> [2-year complete remission after withdrawal of methotrexate in a rectal methotrexate-associated diffuse large B-cell lymphoma]. Rinsho Ketsueki. 2007; 48: 485-490."},{"key":"40","unstructured":"40 Rizzi R, Curci P, Delia M <i>et al.<\/i> Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009; 26: 1-9."},{"key":"41","unstructured":"41 Ishida M, Hodohara K, Yoshii M <i>et al.<\/i> Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Int J Clin Exp Pathol. 2013; 6: 2237-2241."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Yamakawa N, Fujimoto M, Kawabata D <i>et al.<\/i> A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014; 41: 293-299.","DOI":"10.3899\/jrheum.130270"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Kameda T, Dobashi H, Miyatake N <i>et al.<\/i> Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res. 2014; 66: 1302-1309.","DOI":"10.1002\/acr.22306"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Kawano N, Ono N, Kawano S <i>et al.<\/i> Clinical features and outcomes of 9 patients with immunodeficiency-associated lymphoproliferative disorders treated at a single institution. J Clin Exp Hematop. 2014; 54: 187-196.","DOI":"10.3960\/jslrt.54.187"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Kudoh M, Harada H, Matsumoto K <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118: e105-e110.","DOI":"10.1016\/j.oooo.2014.02.029"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Shimizu S, Inokuma D, Murata J <i>et al.<\/i> Cutaneous manifestations of methotrexate-associated lymphoproliferative disorders: report of two cases and a review of the literature. Acta Derm Venereol. 2015; 95: 366-367.","DOI":"10.2340\/00015555-1951"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Ikeda K, Nakamura T, Kinoshita T <i>et al.<\/i> Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation. Clin J Gastroenterol. 2016; 9: 17-21.","DOI":"10.1007\/s12328-015-0624-5"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Matsumoto R, Numata K, Doba N <i>et al.<\/i> A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder. J Med Ultrason. 2016; 43: 545-551.","DOI":"10.1007\/s10396-016-0740-y"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Hatano T, Ohishi M, Yoshimoto G <i>et al.<\/i> Methotrexate-related lymphoproliferative disorder presenting with severe swelling of the elbow joint: A case report. JBJS Case Connect. 2017; 7: e65.","DOI":"10.2106\/JBJS.CC.17.00002"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Takei D, Abe T, Amano H <i>et al.<\/i> Methotrexate-associated primary hepatic malignant lymphoma following hepatectomy: A case report. Int J Surg Case Rep. 2017; 31: 5-9.","DOI":"10.1016\/j.ijscr.2016.12.012"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Oebisu N, Hoshi M, Ieguchi M <i>et al.<\/i> Lymphoproliferative disorder with pathological fracture of the femur in a patient with rheumatoid arthritis treated with methotrexate: A case report. Mol Clin Oncol. 2018; 9: 187-191.","DOI":"10.3892\/mco.2018.1654"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Suzuki E, Kanno T, Kimura S <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorder complicated by severe acute respiratory failure and ileal perforation:a case report. Fukushima J Med Sci. 2018; 64: 82-88.","DOI":"10.5387\/fms.2017-23"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest. 2003; 123: 2150-2153.","DOI":"10.1378\/chest.123.6.2150"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Kawahara A, Tsukada J, Yamaguchi T, Katsuragi T, Higashi T. Reversible methotrexate-associated lymphoma of the liver in rheumatoid arthritis: a unique case of primary hepatic lymphoma. Biomark Res. 2015; 3: 10.","DOI":"10.1186\/s40364-015-0035-2"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Miyagawa K, Shibata M, Noguchi H <i>et al.<\/i> Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis. Intern Med. 2015; 54: 401-405.","DOI":"10.2169\/internalmedicine.54.3361"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010; 101: 1309-1313.","DOI":"10.1111\/j.1349-7006.2010.01517.x"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Ichikawa A, Arakawa F, Kiyasu J <i>et al.<\/i> Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91: 20-28.","DOI":"10.1111\/ejh.12116"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Muto R, Miyoshi H, Sato K <i>et al.<\/i> Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018; 7: 5843-5858.","DOI":"10.1002\/cam4.1805"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Dojcinov SD, Venkataraman G, Pittaluga S <i>et al.<\/i> Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011; 117: 4726-4735.","DOI":"10.1182\/blood-2010-12-323238"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Castillo JJ, Beltran BE, Miranda RN <i>et al.<\/i> EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018; 93: 953-962.","DOI":"10.1002\/ajh.25112"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Oyama T, Yamamoto K, Asano N <i>et al.<\/i> Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007; 13: 5124-5132.","DOI":"10.1158\/1078-0432.CCR-06-2823"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Kawano N, Ono N, Yoshida S <i>et al.<\/i> Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration. J Clin Exp Hematop. 2012; 52: 193-198.","DOI":"10.3960\/jslrt.52.193"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Boulanger E, Rieux-Laucat F, Picard C <i>et al.<\/i> Diffuse large B-cell non-Hodgkin\u2019s lymphoma in a patient with autoimmune lymphoproliferative syndrome. Br J Haematol. 2001; 113: 432-434.","DOI":"10.1046\/j.1365-2141.2001.02749.x"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Lim IG, Bertouch JV. Remission of lymphoma after drug withdrawal in rheumatoid arthritis. Med J Aust. 2002; 177: 500-501.","DOI":"10.5694\/j.1326-5377.2002.tb04919.x"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Hasserjian RP, Chen S, Perkins SL <i>et al.<\/i> Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol. 2009; 22: 1532-1540.","DOI":"10.1038\/modpathol.2009.131"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Kondo S, Tanimoto K, Yamada K <i>et al.<\/i> Mature T\/NK-cell lymphoproliferative disease and Epstein\u2013Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013; 462: 399-407.","DOI":"10.1007\/s00428-013-1389-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Tatsumi G, Ukyo N, Hirata H, Tsudo M. Primary hepatic lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Case Rep Hematol. 2014; 2014: 1-5.","DOI":"10.1155\/2014\/460574"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015; 60: 408-411.","DOI":"10.1111\/adj.12235"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Chang MD, Markham MJ, Liu X. Epstein-Barr virus-positive diffuse large B-cell lymphoma involving the colon in a patient with ulcerative pancolitis and polymyositis on long-term methotrexate therapy. Gastroenterol Res. 2016; 9: 83-86.","DOI":"10.14740\/gr720e"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Tokuyama K, Okada F, Matsumoto S <i>et al.<\/i> EBV-positive MTX-diffuse large B cell lymphoma in a rheumatoid arthritis patient. Jpn J Radiol. 2014; 32: 183-187.","DOI":"10.1007\/s11604-013-0280-y"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Jeon YW, Yoon JH, Lee SE <i>et al.<\/i> Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study. Korean J Intern Med. 2016; 31: 944-952.","DOI":"10.3904\/kjim.2015.097"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Loo EY, Medeiros LJ, Aladily TN <i>et al.<\/i> Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2013; 37: 1290-1297.","DOI":"10.1097\/PAS.0b013e31828e6564"},{"key":"73","unstructured":"73 Takasumi M, Okai K, Asano T <i>et al.<\/i> [A case of methotrexate-associated lymphoproliferative disorder diagnosed by liver biopsy]. Nippon Shokakibyo Gakkai Zasshi. 2015; 112: 115-122."},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Tsukazaki Y, Shinohara T, Tanaka K <i>et al.<\/i> Hepatosplenic Hodgkin lymphoma without lymphadenopathy following reversible methotrexate-associated lymphoproliferative disorder. Mod Rheumatol. 2017; 27: 372-375.","DOI":"10.3109\/14397595.2014.977513"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Eso Y, Uza N, Shirakawa K <i>et al.<\/i> Choledochoduodenal fistula during chemotherapy with brentuximab vedotin for methotrexate-associated lymphoproliferative disorder. Intern Med. 2018; 57: 2203-2207.","DOI":"10.2169\/internalmedicine.0557-17"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Nakazato T, Takanashi S, Hirano M <i>et al.<\/i> Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma. Ann Hematol. 2018; 97: 1489-1491.","DOI":"10.1007\/s00277-018-3279-8"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Svensson AM, Jacobson ER, Ospina D, Tindle BH. Reversible Epstein-Barr virus-negative lymphadenopathy and bone marrow involved by Hodgkin\u2019s lymphoma in a rheumatoid arthritis patient undergoing long-term treatment with low-dose methotrexate: a case report and review of the literature. Int J Hematol. 2006; 83: 47-50.","DOI":"10.1532\/IJH97.NA0503"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010; 34: 405-417.","DOI":"10.1097\/PAS.0b013e3181cf8622"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Carbone A, Spina M, Gloghini A, Tirelli U. Classical Hodgkin\u2019s lymphoma arising in different host\u2019s conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol. 2011; 86: 170-179.","DOI":"10.1002\/ajh.21910"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Miranda RN, Loo E, Medeiros LJ. Iatrogenic immunodeficiency-associated classical hodgkin lymphoma: clinicopathologic features of 54 cases reported in the literature. Am J Surg Pathol. 2013; 37: 1895-1897.","DOI":"10.1097\/PAS.0000000000000095"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Komatsuda A, Wakui H, Nimura T, Sawada K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008; 18: 315-318.","DOI":"10.3109\/s10165-008-0053-0"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Ohkura Y, Shindoh J, Haruta S <i>et al.<\/i> Primary adrenal lymphoma possibly associated with Epstein-Barr virus reactivation due to immunosuppression under methotrexate therapy. Medicine (Baltimore). 2015; 94: e1270.","DOI":"10.1097\/MD.0000000000001270"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Yamakawa H, Yoshida M, Katagi H <i>et al.<\/i> Pulmonary and retroperitoneal lesions induced by methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis. Mod Rheumatol. 2016; 26: 441-444.","DOI":"10.3109\/14397595.2014.898559"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Tsukui D, Kanda H, Shinozaki-Ushiku A <i>et al.<\/i> Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome. Mod Rheumatol. 2018; 28: 621-625.","DOI":"10.1080\/14397595.2017.1387223"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Kikuchi K, Miyazaki Y, Tanaka A <i>et al.<\/i> Methotrexate-related Epstein-Barr Virus (EBV)-associated lymphoproliferative disorder--so-called \u201cHodgkin-like lesion\u201d--of the oral cavity in a patient with rheumatoid arthritis. Head Neck Pathol. 2010; 4: 305-311.","DOI":"10.1007\/s12105-010-0202-6"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Takemori N, Kaneko H, Nakamura M, Kojima M. Complete remission of methotrexate-related Epstein-Barr-virus-associated Hodgkin-like lymphoma following withdrawal of MTX coupled with clarithromycin administration. Case Rep Hematol. 2012; 2012: 1-6.","DOI":"10.1155\/2012\/658745"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Satoh K, Yoshida N, Imaizumi K <i>et al.<\/i> Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis. Am J Med Sci. 2009; 338: 334-335.","DOI":"10.1097\/MAJ.0b013e3181acbb49"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Attard AA, Praveen P, Dunn PJS, James GJ. Epstein-Barr virus\u2013positive mucocutaneous ulcer of the oral cavity: the importance of having a detailed clinical history to reach a correct diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114: e37-e39.","DOI":"10.1016\/j.oooo.2012.04.003"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Hashizume H, Uchiyama I, Kawamura T <i>et al.<\/i> Epstein-Barr virus-positive mucocutaneous ulcers as a manifestation of methotrexate-associated B-cell lymphoproliferative disorders. Acta Derm Venereol. 2012; 92: 276-277.","DOI":"10.2340\/00015555-1274"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Sadasivam N, Johnson RJ, Owen RG. Resolution of methotrexate-induced Epstein-Barr virus-associated mucocutaneous ulcer. Br J Haematol. 2014; 165: 584.","DOI":"10.1111\/bjh.12743"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Moran NR, Webster B, Lee KM <i>et al.<\/i> Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn\u2019s disease. World J Gastroenterol. 2015; 21: 6072-6076.","DOI":"10.3748\/wjg.v21.i19.6072"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Hashimoto K, Nagao T, Saito T, Kinoshita H. Methotrexate-associated lymphoproliferative disorders of the tongue developing in patients with rheumatoid arthritis: a report of 2 cases and a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119: e1-e5.","DOI":"10.1016\/j.oooo.2014.04.002"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Nakauyaca A, Kalro A, Donaldson E, Patel H. Fatal outcome of an Epstein-Barr virus positive mucocutaneous ulcer secondary to methotrexate. Intern Med J. 2016; 46: 1226-1228.","DOI":"10.1111\/imj.13219"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Chen BJ, Fang CL, Chuang SS. Epstein-Barr virus-positive mucocutaneous ulcer. Kaohsiung J Med Sci. 2017; 33: 50-51.","DOI":"10.1016\/j.kjms.2016.08.003"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Furudate K, Satake A, Narita N, Kobayashi W. Methotrexate-related lymphoproliferative disorder in patients with osteonecrosis of the jaw: A 3-case report and literature review. J Oral Maxillofac Surg. 2018; 76: 97-111.","DOI":"10.1016\/j.joms.2017.05.027"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Daroontum T, Kohno K, Eladl AE <i>et al.<\/i> Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan. Histopathology. 2018; 72: 1115-1127.","DOI":"10.1111\/his.13464"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Satou A, Banno S, Hanamura I <i>et al.<\/i> EBV-positive mucocutaneous ulcer arising in rheumatoid arthritis patients treated with methotrexate: single center series of nine cases. Pathol Int. 2019; 69: 21-28.","DOI":"10.1111\/pin.12745"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Daroontum T, Kohno K, Inaguma Y <i>et al.<\/i> Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder. Pathol Int. 2019; 69: 37-41.","DOI":"10.1111\/pin.12738"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol. 2007; 56: 686-690.","DOI":"10.1016\/j.jaad.2006.09.011"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Tanaka A, Shigematsu H, Kojima M, Sakashita H, Kusama K. Methotrexate-associated lymphoproliferative disorder arising in a patient with adult Still\u2019s disease. J Oral Maxillofac Surg. 2008; 66: 1492-1495.","DOI":"10.1016\/j.joms.2007.05.006"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Roberts TK, Chen X, Liao JJ. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. Exp Hematol Oncol. 2015; 5: 13.","DOI":"10.1186\/s40164-016-0042-5"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Makino Y, Tani C, Miyokawa N <i>et al.<\/i> Multiple intestinal ulcers associated with primary Epstein-Barr virus infection in a patient with rheumatoid arthritis undergoing methotrexate therapy. Intern Med. 2015; 54: 2851-2855.","DOI":"10.2169\/internalmedicine.54.4735"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 Au JK, Said JW, Sepahdari AR, St. John MA. Head and neck Epstein-Barr virus mucocutaneous ulcer: case report and literature review. Laryngoscope. 2016; 126: 2500-2504.","DOI":"10.1002\/lary.26009"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Saleh JZ, Lee LH, Schieke SM, Hosking PR, Hwang ST. Methotrexate-induced CD30+ T-cell lymphoproliferative disorder of the oral cavity. JAAD Case Rep. 2016; 2: 354-356.","DOI":"10.1016\/j.jdcr.2016.02.002"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Mishima S, Takahashi K, Tomioka T, Bessho K. Numb chin syndrome as initial manifestation of bisphosphonate-related osteomyelitis of the jaw and methotrexate-associated lymphoproliferative disorders: a rare case. Br J Oral Maxillofac Surg. 2016; 54: 114-115.","DOI":"10.1016\/j.bjoms.2015.10.031"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Hujoel IA, Rubio-Tapia A, Dao LN, Porrata LF, Kane SV. Epstein-Barr virus-positive mucocutaneous ulcer in an immunosuppressed patient. ACG Case Rep J. 2018; 5: e32.","DOI":"10.14309\/crj.2018.32"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Lee YM, Kim JM. Epstein-Barr virus-positive mucocutaneous ulcer colliding with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma) that developed in the palatine tonsils of an immunocompetent patient after gastric lymphoma relapse. Blood Res. 2018; 53: 329-332.","DOI":"10.5045\/br.2018.53.4.329"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 McCormack C, Huang Q. EBV + mucocutaneous ulcer: a new entity of WHO 2017. Blood. 2018; 131: 1993.","DOI":"10.1182\/blood-2018-01-825570"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Namiki T, Sone Y, Miura K, Tanaka M, Yokozeki H. Methotrexate-associated lymphoproliferative disorder: dermoscopic features. Case Rep Dermatol. 2018; 10: 149-153.","DOI":"10.1159\/000489694"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Manipadam MT, Ravi PY, Sigamani E, Jeelani Y. Methotrexate-associated Epstein\u2013Barr virus mucocutaneous ulcer: A case report and review of literature. Indian J Pathol Microbiol. 2018; 61: 255-257.","DOI":"10.4103\/IJPM.IJPM_135_16"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Schwartz Z, Bowe RB, Coleman M, Magro CM. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Ann Diagn Pathol. 2018; 37: 57-61.","DOI":"10.1016\/j.anndiagpath.2018.08.004"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Sinit RB, Horan KL, Dorer RK, Aboulafia DM. Epstein-Barr virus-positive mucocutaneous ulcer: case report and review of the first 100 published cases. Clin Lymphoma Myeloma Leuk. 2019; 19: e81-e92.","DOI":"10.1016\/j.clml.2018.10.003"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Kojima M, Motoori T, Hosomura Y <i>et al.<\/i> Atypical lymphoplasmacytic and immunoblastic proliferation from rheumatoid arthritis: A case report. Pathol Res Pract. 2006; 202: 51-54.","DOI":"10.1016\/j.prp.2005.10.005"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114 Nagai S, Izutsu K, Watanabe T, Kurokawa M. Simultaneous appearance of methotrexate-associated lymphoproliferative disorder and tuberculous meningitis demonstrating the definitive role of immunosuppression. Ann Hematol. 2009; 88: 589-590.","DOI":"10.1007\/s00277-008-0619-0"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115 Joannides AJ, El-Shaboury H, Guirguis R, Fasler JJ, Rajagopal V. Methotrexate-associated lymphoproliferative disorder presenting as disseminated malignancy. Rheumatology. 2011; 50: 1927-1928.","DOI":"10.1093\/rheumatology\/ker214"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116 Fujita T, Tanabe M, Iida E, Okimoto T, Matsunaga N. Multi-modality imaging findings of methotrexate-related Epstein\u2013Barr virus-associated hepatic tumor. Clin Imaging. 2013; 37: 962-964.","DOI":"10.1016\/j.clinimag.2013.05.005"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Fukushima M, Katayama Y, Yokose N <i>et al.<\/i> Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving low-dose methotrexate treatment. Br J Neurosurg. 2013; 27: 824-826.","DOI":"10.3109\/02688697.2013.798857"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 Suemori K, Hasegawa H, Ishizaki J <i>et al.<\/i> Methotrexate-associated lymphoproliferative disease with multiple pulmonary nodules in a patient with rheumatoid arthritis. Intern Med. 2015; 54: 1421-1425.","DOI":"10.2169\/internalmedicine.54.3542"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119 Katsoulas N, Chrysomali E, Piperi E, Levidou G, Sklavounou-Andrikopoulou A. Atypical methotrexate ulcerative stomatitis with features of lymphoproliferative like disorder: report of a rare ciprofloxacin-induced case and review of the literature. J Clin Exp Dent. 2016; 8: e629-e633.","DOI":"10.4317\/jced.52909"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120 Nakamura H, Shibata Y, Takeda T. Sternoclavicular joint swelling in a patient with rheumatoid arthritis. J Rheumatol. 2016; 43: 2074-2075.","DOI":"10.3899\/jrheum.160401"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121 Kobayashi Y, Kimura K, Fujitsu Y <i>et al.<\/i> Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report. Jpn J Ophthalmol. 2016; 60: 212-218.","DOI":"10.1007\/s10384-016-0439-z"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122 Furukawa S, Oobu K, Moriyama M <i>et al.<\/i> Oral methotrexate-related lymphoproliferative disease presenting with severe osteonecrosis of the jaw: A case report and literature review. Intern Med. 2018; 57: 575-581.","DOI":"10.2169\/internalmedicine.8946-17"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 Lai WF, Chin YP, Liu CW, Tsai CY. Methotrexate-associated lymphoproliferative disease with multiple pulmonary nodules in a patient with rheumatoid arthritis. BMJ Case Rep. 2017; 2017.","DOI":"10.1136\/bcr-2017-221778"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Sato N, Toide N, Kizawa M <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorder in a patient with neuromyelitis optica spectrum disorder: an implication for pathogenesis mediated by Epstein-Barr virus. J Neurol Sci. 2017; 379: 219-221.","DOI":"10.1016\/j.jns.2017.06.020"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 Hashimoto K, Akagi M. Lymphoproliferative disorder in an elderly rheumatoid arthritis patient after longterm oral methotrexate administration: A case report. Mol Clin Oncol. 2018; 9: 293-296.","DOI":"10.3892\/mco.2018.1675"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126 Tokuhira M, Tabayashi T, Tanaka Y <i>et al.<\/i> The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis. J Clin Exp Hematop. 2017; 56: 165-169.","DOI":"10.3960\/jslrt.56.165"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Baird RD, Nellis van Zyl-Smit R, Dilke T, Scott SE, Rassam SMB. Spontaneous remission of low-grade B-cell non-Hodgkin\u2019s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol. 2002; 118: 567-568.","DOI":"10.1046\/j.1365-2141.2002.03619.x"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Hoshida Y, Tomita Y, Zhiming D <i>et al.<\/i> Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2004; 108: 443-449.","DOI":"10.1002\/ijc.11582"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Ishigaki S, Masaoka T, Kameyama H <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorder of the stomach presumed to be mucosa-associated lymphoid tissue lymphoma. Intern Med. 2018; 57: 3249-3254.","DOI":"10.2169\/internalmedicine.0737-18"},{"key":"130","unstructured":"130 Katsuragi T, Iwashige A, Tsukada J. [Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis]. Rinsho Ketsueki. 2016; 57: 9-14."},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Kikuchi J, Kaneko Y, Kasahara H <i>et al.<\/i> Methotrexate-associated intravascular large B-cell lymphoma in a patient with rheumatoid arthritis. Intern Med. 2016; 55: 1661-1665.","DOI":"10.2169\/internalmedicine.55.6943"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Hagihara M, Mese T, Ohara S <i>et al.<\/i> Methotrexate-associated intravascular large B-cell lymphoma in a patient with rheumatoid arthritis: A very rare case. Intern Med. 2018; 57: 3001-3005.","DOI":"10.2169\/internalmedicine.0875-18"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Takajo I, Umekita K, Ikei Y, Oshima K, Okayama A. Adult T-cell leukemia\/lymphoma as a methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis. Intern Med. 2018; 57: 2071-2075.","DOI":"10.2169\/internalmedicine.0308-17"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134 Hatanaka K, Nakamura N, Kojima M <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract. 2010; 206: 9-13.","DOI":"10.1016\/j.prp.2009.03.005"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135 Kiyasu J, Arakawa F, Haji S <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis. Pathol Int. 2018; 68: 485-490; Epub ahead of print.","DOI":"10.1111\/pin.12703"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136 Singh BK, Antony PT, Verma SK, Basu D, Negi VS. Anaplastic large cell lymphoma in a patient with systemic onset juvenile arthritis: case report and review of literature. Int J Rheum Dis. 2014; 17: 573-577.","DOI":"10.1111\/1756-185X.12361"},{"key":"137","unstructured":"137 Cornejo CM, Novoa RA, Krisch RE, Kim EJ. Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate. Cutis. 2016; 98: 253-256."},{"key":"138","doi-asserted-by":"crossref","unstructured":"138 Nemoto Y, Taniguchi A, Kamioka M <i>et al.<\/i> Epstein\u2013Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. Int J Hematol. 2010; 92: 364-368.","DOI":"10.1007\/s12185-010-0642-5"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139 Hatachi S, Kunitomi A, Aozasa K, Yagita M. CD8 + T-cell lymphoproliferative disorder associated with Epstein\u2013Barr virus in a patient with rheumatoid arthritis during methotrexate therapy. Mod Rheumatol. 2010; 20: 500-505.","DOI":"10.3109\/s10165-010-0300-z"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140 Koji H, Yazawa T, Nakabayashi K <i>et al.<\/i> CD8-positive T-cell lymphoproliferative disorder associated with Epstein-Barr virus-infected B-cells in a rheumatoid arthritis patient under methotrexate treatment. Mod Rheumatol. 2016; 26: 271-275.","DOI":"10.3109\/14397595.2013.850613"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141 Kamiya Y, Toyoshima M, Suda T. Endobronchial involvement in methotrexate-associated lymphoproliferative disease. Am J Respir Crit Care Med. 2016; 193: 1304-1306.","DOI":"10.1164\/rccm.201512-2338IM"},{"key":"142","unstructured":"142 Terroso G, Aleixo J, Bernardes M <i>et al.<\/i> Nasal type extranodal NK\/T cell lymphoma diagnosed in a patient with rheumatoid arthritis under methotrexate. Acta Reumatol Port. 2014; 39: 77-81."},{"key":"143","doi-asserted-by":"crossref","unstructured":"143 Tajima S, Takanashi Y, Koda K, Fukayama M. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK\/T-cell lymphoma arising in the lungs. Pathol Int. 2015; 65: 661-665.","DOI":"10.1111\/pin.12346"},{"key":"144","unstructured":"144 Uchida T, Inoue M, Hua J <i>et al.<\/i> Iatrogenic immunodeficiency-associated Epstein-Barr virus (EBV) -negative natural killer cell lymphoproliferative disorder in a patient undergoing rheumatoid arthritis therapy. Rinsho Ketsueki. 2017; 58: 624-629."},{"key":"145","unstructured":"145 Sliesoraitis S, Khan R, Rothman J. Methotrexate-induced Hodgkin disease in a patient with systemic lupus erythematosus. J Am Osteopath Assoc. 2009; 109: 325-328."},{"key":"146","doi-asserted-by":"crossref","unstructured":"146 Dong L, Chen Y, Masaki Y, Okazaki T, Umehara H. Possible mechanisms of lymphoma development in Sjogren\u2019s syndrome. Curr Immunol Rev. 2013; 9: 13-22.","DOI":"10.2174\/1573395511309010003"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147 Tarella C, Gueli A, Ruella M, Cignetti A. Lymphocyte transformation and autoimmune disorders. Autoimmun Rev. 2013; 12: 802-813.","DOI":"10.1016\/j.autrev.2012.11.004"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148 Lam GY, Halloran BP, Peters AC, Fedorak RN. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders. World J Gastrointest Pathophysiol. 2015; 6: 181-192.","DOI":"10.4291\/wjgp.v6.i4.181"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149 Pereira VPL, Robazzi TCMV. Biological therapy and development of neoplastic disease in patients with juvenile rheumatic disease: a systematic review. Rev Bras Reumatol Engl Ed. 2017; 57: 174-181.","DOI":"10.1016\/j.rbre.2016.11.008"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150 Smedby KE, Ponzoni M. The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. J Intern Med. 2017; 282: 360-370.","DOI":"10.1111\/joim.12684"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151 Yang C, Huang J, Huang X <i>et al.<\/i> Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: A systematic review and meta-analysis. J Crohn\u2019s Colitis. 2018; [Epub ahead of print].","DOI":"10.1093\/ecco-jcc\/jjy065"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152 Rom\u00e3o VC, Talarico R, Scir\u00e8 CA <i>et al.<\/i> Sj\u00f6gren\u2019s syndrome: state of the art on clinical practice guidelines. RMD Open. 2018; 4(suppl 1): e000789.","DOI":"10.1136\/rmdopen-2018-000789"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153 Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leuk Res. 2018; 75: 45-49.","DOI":"10.1016\/j.leukres.2018.11.004"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154 Leli\u00e8vre JD, Sacre K, Adle-Biassette H <i>et al.<\/i> Epstein-Barr virus\u2013associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: A case of spontaneous regression. J Am Acad Dermatol. 2005; 52(suppl 1): S24-S27.","DOI":"10.1016\/j.jaad.2004.06.043"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155 Dubey S, Adebajo AO. Lymphoproliferative disorder due to sulphasalazine. BMJ Case Rep. 2009; 2009.","DOI":"10.1136\/bcr.06.2008.0038"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156 Ikeda T, Toyama S, Ogasawara M <i>et al.<\/i> Rheumatoid arthritis complicated with immunodeficiency-associated lymphoproliferative disorders during treatment with adalimumab. Mod Rheumatol. 2012; 22: 458-462.","DOI":"10.3109\/s10165-011-0501-0"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157 McGinness JL, Spicknall KE, Mutasim DF. Azathioprine-induced EBV-positive mucocutaneous ulcer. J Cutan Pathol. 2012; 39: 377-381.","DOI":"10.1111\/j.1600-0560.2011.01829.x"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158 Oda K, Minata M. Drug free remission after steroid-dependent disappearance of lymphoproliferative disorder in rheumatoid arthritis patient treated with TNF-alpha blockade: case study. Springerplus. 2015; 4: 41.","DOI":"10.1186\/s40064-015-0798-9"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159 Nosotti L, Baiocchini A, Bonifati C <i>et al.<\/i> Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis. World J Hepatol. 2015; 7: 814-818.","DOI":"10.4254\/wjh.v7.i5.814"},{"key":"160","unstructured":"160 D\u2019Haens G, Reinisch W, Colombel JF <i>et al.<\/i>. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab [Remicade(R)] or conventional therapy. J Crohn\u2019s Colitis. 2017; 11: 680-689."},{"key":"161","doi-asserted-by":"crossref","unstructured":"161 Okada K, Asakura S, Yano T, Kishimoto T. EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus. Int J Hematol. 2018; 108: 329-334.","DOI":"10.1007\/s12185-018-2426-2"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162 Tokuhira M, Saito S, Suzuki K <i>et al.<\/i> Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. Leuk Lymphoma. 2019; 5: 1-8.","DOI":"10.1080\/10428194.2019.1585841"},{"key":"163","unstructured":"163 Singh JA, Saag KG, Bridges SL Jr <i>et al.<\/i> 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68: 1-26."},{"key":"164","unstructured":"164 https:\/\/www.ryumachi-jp.com\/publication\/pdf\/MTX2016kanni.pdf."},{"key":"165","unstructured":"165 Kameda H, Fujii T, Nakajima A <i>et al.<\/i> Japan college of rheumatology guideline for the use of methotrexate in patients with rheumastoid arthritis. Mod Rheumatol. 2018; 24: 1-10."},{"key":"166","doi-asserted-by":"crossref","unstructured":"166 Stevens SJC, Verschuuren EA, Pronk I <i>et al.<\/i> Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001; 97: 1165-1171.","DOI":"10.1182\/blood.V97.5.1165"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167 Wagner HJ, Wessel M, Jabs W <i>et al.<\/i> Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001; 72: 1012-1019.","DOI":"10.1097\/00007890-200109270-00006"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168 Tsai DE, Douglas L, Andreadis C <i>et al.<\/i> EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant. 2008; 8: 1016-1024.","DOI":"10.1111\/j.1600-6143.2008.02183.x"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169 Luskin MR, Heil DS, Tan KS <i>et al.<\/i> The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015; 15: 2665-2673.","DOI":"10.1111\/ajt.13324"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170 Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med. 1981; 305: 1238-1243.","DOI":"10.1056\/NEJM198111193052102"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171 Toussirot E, Wendling D, Tiberghien P, Luka J, Roudier J. Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Ann Rheum Dis. 2000; 59: 533-538.","DOI":"10.1136\/ard.59.7.533"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172 Balandraud N, Meynard JB, Auger I <i>et al.<\/i> Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003; 48: 1223-1228.","DOI":"10.1002\/art.10933"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173 Feng W, Cohen JI, Fischer S <i>et al.<\/i> Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. JNCI Journal of the National Cancer Institute. 2004; 96: 1691-1702.","DOI":"10.1093\/jnci\/djh313"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174 Balandraud N, Roudier J. Epstein-Barr virus and rheumatoid arthritis. Joint Bone Spine. 2018; 85: 165-170.","DOI":"10.1016\/j.jbspin.2017.04.011"},{"key":"175","unstructured":"175 Kuusela E, Kouri VP, Olkkonen J <i>et al.<\/i> Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018; 36: 778-784."},{"key":"176","doi-asserted-by":"crossref","unstructured":"176 Kawada J, Iwata N, Kitagawa Y, Kimura H, Ito Y. Prospective monitoring of Epstein\u2013Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab. Mod Rheumatol. 2012; 22: 565-570.","DOI":"10.3109\/s10165-011-0552-2"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177 Miceli-Richard C, Gestermann N, Amiel C <i>et al.<\/i> Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther. 2009; 11: R77.","DOI":"10.1186\/ar2708"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178 Balandraud N, Texier G, Massy E <i>et al.<\/i> Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study. PLoS One. 2017; 12: e0171623.","DOI":"10.1371\/journal.pone.0171623"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179 Fujieda M, Tsuruga K, Sato T <i>et al.<\/i> Monitoring of Epstein\u2013Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab. Mod Rheumatol. 2017; 27: 66-71.","DOI":"10.1080\/14397595.2016.1177247"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/2\/59_19007\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T10:03:02Z","timestamp":1721469782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/2\/59_19007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.19007","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}